Streetbeat News

Products Services

GILD

Gilead Sciences announced that the Phase 3 EVOKE-01 study results for metastatic NSCLC will be presented at ASCO 2024. The study did not meet its primary endpoint of overall survival.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:16 pm

AUTL

Autolus Therapeutics presented additional data from its Phase 2 FELIX study of obe-cel for adult r/r B-ALL at the ASCO Annual Meeting. The data showed durable responses in the majority of patients, with 40% in ongoing remission without further intervention. The company will discuss the data in a webcast on June 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:11 pm

AIXI

Xiao-I Corporation has signed an agreement to implement its live chat AI system for a client in the automotive industry.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:11 pm

LIPO

Lipella Pharmaceuticals has completed the site initiation visit for its Phase 2a trial of LP-310, a treatment for Oral Lichen Planus. Clinical testing is expected to begin in mid-2024.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:04 pm

PFE

Pfizer's Phase 3 CROWN trial shows that 60% of patients with ALK-positive advanced lung cancer treated with LORBRENA remain alive without disease progression after five years, compared to 8% with XALKORI. The study also shows an 81% reduction in the risk of progression or death and a 94% reduction in brain metastases progression with LORBRENA.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:04 pm

BKSY

BlackSky Technology Inc. (NYSE:BKSY) has secured a $7 million contract renewal to provide space-based imagery and analytics monitoring services to an international government customer. The contract highlights BlackSky's capability to deliver high-frequency, low-latency imagery and analytics with a software-first approach.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:03 pm

ITRM

Iterum Therapeutics has received FDA acceptance for its resubmission of a New Drug Application (NDA) for oral sulopenem, aimed at treating uncomplicated urinary tract infections.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:03 pm

RIVN

Rivian Automotive, Inc. (NASDAQ:RIVN) CEO R.J. Scaringe warned investors of a challenging Q2 2024 due to production disruptions from integrating new equipment and robots at their Illinois factory. Despite a strong initial response to the upcoming R2 SUV and exceeding Q1 revenue expectations, Rivian reported a significant net loss and high per-vehicle loss. The company aims to produce 57,000 vehicles in 2024 and achieve a positive gross margin by Q4.

Portfolio Pulse from Anan Ashraf

May 31, 2024 | 11:47 am

ADAP

Adaptimmune Therapeutics shares are trading higher after the company and Galapagos entered a clinical collaboration to license Adaptimmune's uza-cel in head & neck cancer.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:47 am

SMMT

Summit Therapeutics shares are trading lower after a significant rise of over 270% on Thursday due to positive cancer data.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:46 am